Second response to lower-dose thalidomide in a patient with multiple myeloma
- PMID: 12043696
- DOI: 10.1182/blood.v99.11.4248
Second response to lower-dose thalidomide in a patient with multiple myeloma
Comment on
-
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood. 2001 Jul 15;98(2):492-4. doi: 10.1182/blood.v98.2.492. Blood. 2001. PMID: 11435324 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
